Clinical trial · Observational
Lynparza Breast Cancer Clinical Experience Investigation
Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy
NCT03590938CI-TRIAL-00064780completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Adverse drug reactions of bone marrow depression
- timeFrame
- One year period
- description
- Bone marrow depression will be investigated as safety specification topics
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy Exclusion Criteria: * The patients who are not started on Lymparza for the first time
References
Publications (0)
Data not yet available
No reference posted for this study.